HK1204571A1 - Protease-regulated antibodies - Google Patents

Protease-regulated antibodies

Info

Publication number
HK1204571A1
HK1204571A1 HK15105185.7A HK15105185A HK1204571A1 HK 1204571 A1 HK1204571 A1 HK 1204571A1 HK 15105185 A HK15105185 A HK 15105185A HK 1204571 A1 HK1204571 A1 HK 1204571A1
Authority
HK
Hong Kong
Prior art keywords
protease
regulated antibodies
antibodies
regulated
Prior art date
Application number
HK15105185.7A
Other languages
English (en)
Chinese (zh)
Inventor
Zhuozhi Wang
Ruth Winter
John Murphy
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HK1204571A1 publication Critical patent/HK1204571A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HK15105185.7A 2012-03-30 2015-06-01 Protease-regulated antibodies HK1204571A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261617837P 2012-03-30 2012-03-30
PCT/US2013/031363 WO2013148248A1 (fr) 2012-03-30 2013-03-14 Anticorps régulés par les protéases

Publications (1)

Publication Number Publication Date
HK1204571A1 true HK1204571A1 (en) 2015-11-27

Family

ID=49261048

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105185.7A HK1204571A1 (en) 2012-03-30 2015-06-01 Protease-regulated antibodies

Country Status (16)

Country Link
US (2) US9975962B2 (fr)
EP (1) EP2841082A4 (fr)
JP (2) JP6283017B2 (fr)
KR (1) KR20150030639A (fr)
CN (2) CN107266574A (fr)
AU (1) AU2013240279A1 (fr)
BR (1) BR112014024373A2 (fr)
CA (1) CA2868789A1 (fr)
HK (1) HK1204571A1 (fr)
IL (1) IL234848A0 (fr)
MX (1) MX2014011781A (fr)
RU (1) RU2014143639A (fr)
SG (1) SG11201406129QA (fr)
TW (1) TW201402605A (fr)
WO (1) WO2013148248A1 (fr)
ZA (1) ZA201407897B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266574A (zh) 2012-03-30 2017-10-20 拜尔健康护理有限责任公司 蛋白酶调节的抗体
WO2014144577A1 (fr) 2013-03-15 2014-09-18 Bayer Healthcare Llc Variants d'anticorps anti-tfpi avec liaison modulable sur une gamme de ph pour améliorer les propriétés pharmacologiques
AU2014274215B2 (en) 2013-05-28 2019-02-28 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
JP6783754B2 (ja) 2014-09-17 2020-11-11 ノヴォ ノルディスク アー／エス 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
CA2977621C (fr) 2015-02-25 2021-11-23 Mogam Institute For Biomedical Research Nouvel anticorps se liant a la tfpi et composition le comprenant
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CN107922506B (zh) 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
MX2018014227A (es) 2016-05-20 2019-08-22 Harpoon Therapeutics Inc Proteinas de union de cadena unica de fragmento variable cd3.
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR20190087539A (ko) 2016-11-23 2019-07-24 하푼 테라퓨틱스, 인크. Psma 표적화 삼중특이성 단백질 및 사용 방법
EA201991168A1 (ru) 2016-11-23 2019-12-30 Харпун Терапьютикс, Инк. Белок, связывающий простатический специфический мембранный антиген
KR102533814B1 (ko) * 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
TWI797097B (zh) 2016-11-28 2023-04-01 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
MX2019006624A (es) 2016-12-09 2019-08-01 Seattle Genetics Inc Anticuerpos bivalentes enmascarados por helices superenrolladas.
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
BR112019023855B1 (pt) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc Proteínas de ligação à mesotelina
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
WO2018215506A1 (fr) * 2017-05-23 2018-11-29 Université De Genève Peptide dérivé de la bêta-2-glycoprotéine 1 et son utilisation pour le traitement du syndrome des antiphospholipides
CN111630070A (zh) 2017-10-13 2020-09-04 哈普恩治疗公司 三特异性蛋白质及使用方法
AU2018346955A1 (en) 2017-10-13 2020-04-30 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
BR112020010248A2 (pt) * 2017-11-28 2020-11-10 Chugai Seiyaku Kabushiki Kaisha molécula de ligação do ligante tendo atividade de ligação do ligante ajustável
CA3100327A1 (fr) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Fraction de liaison pour l'activation conditionnelle de molecules d'immunoglobuline
CA3114038A1 (fr) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Proteines de liaison a dll3 et methodes d'utilisation
CA3170833A1 (fr) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Proteines de liaison a flt3 et methodes d'utilisation
GB202216284D0 (en) * 2022-11-02 2022-12-14 Ucl Business Ltd Self-regulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE384783T1 (de) 2001-10-19 2008-02-15 Zymogenetics Inc Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
JP2008506389A (ja) * 2004-07-13 2008-03-06 セル ジェネシス インコーポレイテッド Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
EP2178914A2 (fr) * 2007-08-15 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Anticorps monospécifiques et multispécifiques, et procédés d'utilisation
US8426561B2 (en) 2007-11-27 2013-04-23 Francina C. Chahal Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
WO2011109452A1 (fr) * 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimisation d'anticorps monoclonaux dirigés contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
US9260518B2 (en) 2010-06-30 2016-02-16 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
RS58633B1 (sr) * 2011-04-01 2019-05-31 Bayer Healthcare Llc Monoklonalna antitela protiv inhibitora puta tkivnog faktora (tfpi)
CN107266574A (zh) 2012-03-30 2017-10-20 拜尔健康护理有限责任公司 蛋白酶调节的抗体
CN103509115B (zh) * 2012-06-21 2016-03-23 中国科学院上海生命科学研究院 人胱抑素c纳米抗体及其应用
CN104177496B (zh) * 2014-09-02 2015-03-11 安源生物科技(上海)有限公司 人IgG2抗体铰链区修饰体

Also Published As

Publication number Publication date
CN107266574A (zh) 2017-10-20
WO2013148248A1 (fr) 2013-10-03
IL234848A0 (en) 2014-12-31
JP2015514085A (ja) 2015-05-18
US20150064169A1 (en) 2015-03-05
ZA201407897B (en) 2016-05-25
CN104185474A (zh) 2014-12-03
US20180251570A1 (en) 2018-09-06
CN104185474B (zh) 2017-08-25
EP2841082A1 (fr) 2015-03-04
BR112014024373A2 (pt) 2017-08-08
CA2868789A1 (fr) 2013-10-03
TW201402605A (zh) 2014-01-16
RU2014143639A (ru) 2016-05-27
KR20150030639A (ko) 2015-03-20
EP2841082A4 (fr) 2015-12-30
AU2013240279A1 (en) 2014-10-16
JP6283017B2 (ja) 2018-02-21
JP2018064579A (ja) 2018-04-26
MX2014011781A (es) 2014-11-26
US9975962B2 (en) 2018-05-22
SG11201406129QA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
IL264558A (en) Anti–il–23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2930240A4 (fr) Anticorps anti-folr1
EP2844290A4 (fr) Nouveaux anticorps
ZA201407316B (en) Anti-fgfr2 antibody
EP2832855A4 (fr) Nouvel anticorps anti-siglec-15
EP2826790A4 (fr) Anticorps anti-gremlin 1
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HUE054362T2 (hu) Foszfolipáz D4 elleni antitest
PL2935330T3 (pl) Przeciwciała przeciw notch3
EP2804876A4 (fr) Nouveaux anticorps
GB201220242D0 (en) Antibody
EP2848633A4 (fr) Anticorps anti-cxadr
EP2811018A4 (fr) ANTI-CORPS ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220312